Samantha LoRusso

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update

Angela Dispenzieri, Teresa Coelho, Isabel Conceição et al. · Orphanet Journal of Rare Diseases · 2022 · 89 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey

José Nativi-Nicolau, Alfonso Siu, Angela Dispenzieri et al. · JACC CardioOncology · 2021 · 61 citations · Full text

Medicine, Cardiology, Pathology +14

Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

Samantha LoRusso, Nicholas E. Johnson, Michael McDermott et al. · BMC Neurology · 2019 · 57 citations · Full text

Medicine, Biomedical Sciences, Pharmacology +13

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Courtney Campbell, Samantha LoRusso, Angela Dispenzieri et al. · Cardiology and Therapy · 2022 · 47 citations · Full text

Life Sciences, Genetics, Pathology +12